Skip to search formSkip to main contentSkip to account menu

atrasentan

Known as: (2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid, 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid, atrasentan [Chemical/Ingredient] 
A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists.
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

A 127722Xinlay
A 147627ABT 627atrasentan hydrochloride

Broader (2)

Endothelin receptor antagonistPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Denosumab treatment of giant cell tumour of bone.
2012
2012
Preliminary indication of survival benefit from ERCC1 and RRM1‐tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis
Excision repair cross complementing 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) are molecular determinants that predict… 
Highly Cited
2009
Highly Cited
2009
Mechanisms operated by endothelin ETA and ETB receptors in the trigeminal ganglion contribute to orofacial thermal hyperalgesia induced by infraorbital nerve constriction in rats
2009
2009
ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats
ABT-869 is a novel multitargeted inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor… 
2009
2009
Roles of endothelin ETA and ETB receptors in nociception and chemical, thermal and mechanical hyperalgesia induced by endothelin-1 in the rat hindpaw
Review
2007
Review
2007
Chemotherapy for the treatment of hormone‐refractory prostate cancer
Aims:  This review aims at analysing the published literature on chemotherapy for hormone‐refractory prostate cancer (HRPC) to… 
2006
2006
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer
Metastatic prostate cancer is characterized by the presence of osteoblastic bone metastases. Bone metastases account for most of… 
Highly Cited
2005
Highly Cited
2005
Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer
4563 Background: Atrasentan (Xinlay), a selective endothelin-A receptor antagonist, has been studied in 2 randomized placebo… 
2005
2005
Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma
Mitogenic and anti‐apoptotic actions of endothelin‐1 (ET‐1) are mediated through endothelin A (ETA) receptors. We investigated… 
2004
2004
Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies
Purpose: Atrasentan is an orally bioavailable selective antagonist of the endothelin receptor ETA. Due to the potential activity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)